Daniel G. Eramian
Keine laufenden Positionen mehr
Profil
Daniel G.
Eramian worked as the Director of Public Affairs at the US Department of Justice.
He then worked as the Executive Vice President of Corporate Communications at CTI BioPharma Corp.
from 2006 to 2012.
After that, he worked as the Vice President of Communications at Biotechnology Innovation Organization.
Eramian holds an undergraduate degree from the University of Massachusetts and a graduate degree from Suffolk University.
Ehemalige bekannte Positionen von Daniel G. Eramian
| Unternehmen | Position | Ende |
|---|---|---|
| CTI BIOPHARMA CORP. | Public Communications Contact | 27.12.2012 |
| US Department of Justice | Public Communications Contact | - |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Public Communications Contact | - |
Ausbildung von Daniel G. Eramian
| University of Massachusetts | Undergraduate Degree |
| Suffolk University | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
CTI BioPharma Corp.
 CTI BioPharma Corp. Pharmaceuticals: MajorHealth Technology CTI BioPharma Corp. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. It focuses on evaluating pacritinib, its sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA. | Health Technology |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Commercial Services |
| US Department of Justice | Government |
